Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO<sup>®</sup> I.V. Infusion 10 mg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)-Reference-Cited by-同舟云学术

Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO^® I.V. Infusion 10 mg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)

Published:2022 Issue:1 Volume:157 Page:62-75
ISSN:0015-5691
Container-title:Folia Pharmacologica Japonica
language:en
Short-container-title:Folia Pharmacol. Jpn.

Author:

Yamamoto Ryuji¹,Kawashima Satoshi²

Affiliation:

1. Pharmacology & Toxicology Unit, Drug Discovery Research Institute, Research Division, JCR Pharmaceuticals Co., Ltd.

2. Planning Department, Development Division, JCR Pharmaceuticals Co., Ltd.

Publisher

Japanese Pharmacological Society

Subject

Pharmacology

Link

https://www.jstage.jst.go.jp/article/fpj/157/1/157_21080/_pdf

Reference38 articles.

1. 1) Neufeld EF, et al. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. McGraw-Hill; 2001. p. 3421-3452.

2. 2) 田中あけみ. 先天代謝異常症候群（第2版）下. 株式会社日本臨牀社; 2012. p. 533-538.

3. 3) 奥山虎之. ムコ多糖症. 小児内科41増刊号; 2009. 41. p. 466-470.

4. 4) Muenzer J, et al. Eur J Pediatr. 2012;171:181-188.

5. 5) Tanaka A, et al. Mol Genet Metab. 2012;107:513-520.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond;BioDrugs;2024-08-23

2. The solute carrier SLC7A1 may act as a protein transporter at the blood-brain barrier;European Journal of Cell Biology;2024-06

3. Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan;Molecular Genetics and Metabolism Reports;2023-12

4. The Experiences and Challenges of Mothers of Adult Patients with Mucopolysaccharidosis; Mothers of Adults with Severe Mucopolysaccharidosis;Asian Journal of Human Services;2023-10-30

5. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier;Molecular Therapy;2023-03